Effect of Carvedilol Rapid Up-Titration in Patients With Heart Failure With Reduced Ejection Fraction

• Status: Recruiting
• Trial end date: 2022-03-30
• Target enrollment: 0
• Participant gender: All

Summary

Guidelines-directed medical therapy has improved dramatically outcomes in heart failure with reduced ejection fraction (HFrEF) patients. Beta-blockers have the most beneficial effects on all caused mortality and rehospitalization on HFrEF, but unfortunately, since the discovery of beta-blocker therapy in HFrEF, there was no change in the way of titration, start low go slow, which resulted in difficulties in reaching optimal doses for some patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Universitas Sebelas Maret
• Treatments: Carvedilol

Criteria

Inclusion Criteria:

• Acute heart failure patient with reduced ejection fraction in Universitas Sebelas Maret Hospital with naive betablocker therapy

• Age >18 years old

• Initial Heart Rate > 50 bpm

Exclusion Criteria:

• Cardiogenic Shock

• Septicaemia

• High degree AV Block or on pace maker

• History of beta blocker intolerance

• Reactive Pulmonary disease

• Severe Peripheral artery disease

• Creatinine level > 2.5 mg/dl

• Potassium serum >5 mmol/L